Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Plitidepsin in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
2015-001909-14Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- Feb 2016
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in angioimmunoblastic T-cell lymphoma (AITL), sponsored by PharmaMar. Primary endpoint: Overall response rate (ORR) by independent review. Started Feb 2016; status: terminated.
02
Drugs
plitidepsin
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on 2015-001909-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001909-14.